Ribolia
2 known investors
Ribo Life Science (Ribocure/瑞博生物, HKEX: 06938.HK) develops RNA interference (RNAi) technology and industrializes small nucleic acid (siRNA) drugs, with an integrated research platform covering delivery and chemical modification technologies. Its pipeline targets cardiovascular, metabolic, renal, and liver diseases, with a focus on chronic disease treatment.
BiotechDeep TechHealthtech
Investors · 2
Frequently asked questions
- What does Ribolia do?
- Ribo Life Science (Ribocure/瑞博生物, HKEX: 06938.HK) develops RNA interference (RNAi) technology and industrializes small nucleic acid (siRNA) drugs, with an integrated research platform covering delivery and chemical modification technologies. Its pipeline targets cardiovascular, metabolic, renal, and liver diseases, with a focus on chronic disease treatment.
- Who are Ribolia's investors?
- Ribolia's investors include Blue Ocean Capital Group, Pan-Lin Capital.